

Novo A/S appoints Peter Haahr as new CFO

Press release, 6 October 2016

Peter Haahr, 48, has been appointed as the new Chief Financial Officer of Novo A/S with effect from 1 November 2016. He joins Novo A/S from a position as Corporate Vice President, Head of Strategy & Business Development at Novo Nordisk. He has been with Novo Nordisk in various leading positions since 2000.

Kasim Kutay, CEO of Novo A/S says: "I am delighted that Peter is joining Novo A/S as CFO. I have known Peter for over three years and have been impressed by his judgement and values. Peter has an in-depth knowledge of our business and broad skills, which made him the ideal candidate for this role at Novo A/S. From his long and successful career at Novo Nordisk, Peter brings a proven track record that includes investor relations, financial and strategic planning, operational roles and M&A execution."

Peter Haahr started his career as an equity analyst and joined Novo Nordisk from the capital markets in 2000 as Vice President, Head of Investor Relations. Since then he has held various positions, including seven years in operations outside Denmark, before being appointed Corporate Vice President, Head of Strategy & Business Development in 2013.

Peter Haahr says: "It's a great opportunity to be able to use my knowledge and experience to support and further develop the financial strategy and historically impressive results of Novo A/S. I am really looking forward to contribute to the further strengthening of the financial platform that enables the Novo Nordisk Foundation to continue increasing its contribution to society."

Peter Haahr holds an MSc in Finance and Accounting from Aarhus School of Business and an Executive MBA from IMD. He is married and has two sons aged 14 and 15.

About Novo A/S

Novo A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation.

Novo A/S is the holding company in the Novo Group and responsible for managing the Foundation's assets. Besides being the major shareholder in the Novo Group companies, Novo A/S provides seed and venture capital to development-stage companies, takes significant ownership positions in well-established companies within the life sciences and manages a broad portfolio of financial assets. Read more at www.novo.dk.

About the Novo Nordisk Foundation

The Novo Nordisk Foundation is an independent Danish foundation with corporate interests. Its history dates back to 1923.

The objectives of the Foundation are: 1) to provide a stable basis for the commercial and research activities of the companies in the Novo Group; and 2) to support scientific, humanitarian and social purposes.

The vision of the Foundation is to contribute significantly to research and development that improves the health and welfare of people. Since 2010, the Foundation has donated more than DKK 9 billion (€1.2 billion), primarily for research and diabetes treatment at public research institutions and hospitals in Denmark and the other Nordic countries. Read more at www.novonordiskfoundation.com.

Further information

Christian Mostrup Scheel, Press Officer, cims@novo.dk, +45 3067 4805